180 related articles for article (PubMed ID: 31596164)
1. Temsirolimus metabolic pathways revisited.
Shokati T; Hartmann M; Davari B; Klawitter J; Klawitter J; Christians U
Xenobiotica; 2020 Jun; 50(6):640-653. PubMed ID: 31596164
[TBL] [Abstract][Full Text] [Related]
2. Structural identification of SAR-943 metabolites generated by human liver microsomes in vitro using mass spectrometry in combination with analysis of fragmentation patterns.
Strom T; Shokati T; Klawitter J; Klawitter J; Hoffman K; Schiebel HM; Christians U
J Mass Spectrom; 2011 Jul; 46(7):615-24. PubMed ID: 21671437
[TBL] [Abstract][Full Text] [Related]
3. Structural Identification of Zotarolimus (ABT-578) Metabolites Generated by Human Liver Microsomes Using Ion-Trap and High-Resolution Time-of-Flight Mass Spectrometry in Combination with the Analysis of Fragmentation Patterns.
Shokati T; Drake SH; Zhao W; Klawitter J; Klawitter J; Christians U
Metabolites; 2023 Oct; 13(10):. PubMed ID: 37887418
[TBL] [Abstract][Full Text] [Related]
4. In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites.
Cai P; Tsao R; Ruppen ME
Drug Metab Dispos; 2007 Sep; 35(9):1554-63. PubMed ID: 17540708
[TBL] [Abstract][Full Text] [Related]
5. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients.
Strom T; Haschke M; Zhang YL; Bendrick-Peart J; Boyd J; Roberts M; Arabshahi L; Marbach P; Christians U
Ther Drug Monit; 2007 Oct; 29(5):592-9. PubMed ID: 17898649
[TBL] [Abstract][Full Text] [Related]
6. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
[TBL] [Abstract][Full Text] [Related]
7. Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes.
Kong TY; Kim JH; Choi WG; Lee JY; Kim HS; Kim JY; In MK; Lee HS
Anal Bioanal Chem; 2017 Feb; 409(6):1667-1680. PubMed ID: 27924364
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
Desta Z; Ward BA; Soukhova NV; Flockhart DA
J Pharmacol Exp Ther; 2004 Sep; 310(3):1062-75. PubMed ID: 15159443
[TBL] [Abstract][Full Text] [Related]
9. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes.
Streit F; Christians U; Schiebel HM; Meyer A; Sewing KF
Drug Metab Dispos; 1996 Nov; 24(11):1272-8. PubMed ID: 8937863
[TBL] [Abstract][Full Text] [Related]
10. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
Sutton D; Butler AM; Nadin L; Murray M
J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567
[TBL] [Abstract][Full Text] [Related]
11. Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus.
Strom T; Haschke M; Boyd J; Roberts M; Arabshahi L; Marbach P; Christians U
Ther Drug Monit; 2007 Dec; 29(6):743-9. PubMed ID: 18043471
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the NADPH-dependent metabolism of 17beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5.
Lee AJ; Kosh JW; Conney AH; Zhu BT
J Pharmacol Exp Ther; 2001 Aug; 298(2):420-32. PubMed ID: 11454902
[TBL] [Abstract][Full Text] [Related]
14. Enzyme kinetic study of a new cardioprotective agent, KR-32570 using human liver microsomes and recombinant CYP isoforms.
Kim H; Seo KA; Kim H; Lee HS; Lee CH; Shin JG; Liu KH
Arch Pharm Res; 2007 Apr; 30(4):469-74. PubMed ID: 17489363
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
Baldwin SJ; Clarke SE; Chenery RJ
Br J Clin Pharmacol; 1999 Sep; 48(3):424-32. PubMed ID: 10510156
[TBL] [Abstract][Full Text] [Related]
16. In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes.
Kim H; Kang S; Kim H; Yoon YJ; Cha EY; Lee HS; Kim JH; Yea SS; Lee SS; Shin JG; Liu KH
Rapid Commun Mass Spectrom; 2006; 20(5):837-43. PubMed ID: 16470676
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism.
Wu WN; McKown LA; Reitz AB
Eur J Drug Metab Pharmacokinet; 2006; 31(4):277-83. PubMed ID: 17315539
[TBL] [Abstract][Full Text] [Related]
18. Identification and kinetics of microsomal and recombinant equine liver cytochrome P450 enzymes responsible for in vitro metabolism of omeprazole.
Ferlini Agne G; Somogyi AA; Sykes B; Knych H; Franklin S
Biochem Pharmacol; 2023 Aug; 214():115635. PubMed ID: 37285945
[TBL] [Abstract][Full Text] [Related]
19. Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-cineole, a monoterpene cyclic ether, by rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Xenobiotica; 2001 Oct; 31(10):713-23. PubMed ID: 11695850
[TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
